Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Accumulated Depreciation: 2022-2024

  • Stoke Therapeutics' Accumulated Depreciation rose 32.63% to $8.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $8.8 million, marking a year-over-year increase of 32.63%. This contributed to the annual value of $8.8 million for FY2024, which is 32.63% up from last year.
  • Per Stoke Therapeutics' latest filing, its Accumulated Depreciation stood at $8.8 million for Q4 2024, which was up 32.63% from $6.7 million recorded in Q4 2023.
  • In the past 5 years, Stoke Therapeutics' Accumulated Depreciation ranged from a high of $8.8 million in Q4 2024 and a low of $4.2 million during Q4 2022.
  • In the last 3 years, Stoke Therapeutics' Accumulated Depreciation had a median value of $6.7 million in 2023 and averaged $6.6 million.
  • Data for Stoke Therapeutics' Accumulated Depreciation shows a peak YoY soared of 58.57% (in 2023) over the last 5 years.
  • Stoke Therapeutics' Accumulated Depreciation (Quarterly) stood at $4.2 million in 2022, then soared by 58.57% to $6.7 million in 2023, then soared by 32.63% to $8.8 million in 2024.
  • Its Accumulated Depreciation was $8.8 million in Q4 2024, compared to $6.7 million in Q4 2023 and $4.2 million in Q4 2022.